Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2010

View Archived Issues

Solithromycin shows potential against Plasmodium spp. and Mycobacterium leprae

HM-A42 ameliorates disease symptoms in models of asthma, RA and MS

First-in-human data presented on OMP-21M18 in solid tumors

CTAP-201 shows promise in patients with secondary hyperparathyroidism on hemodialysis

Anacetrapib is efficacious and safe in phase III DEFINE trial

Resolvyx Pharma divulges novel resolvin agents for ophthalmic disorders

Abbott discloses new agents for HCV infections

Boehringer Ingelheim and f-star collaborate to discover therapeutic antibodies

ImmunGene receives U.S. government grant for antibody-cytokine fusion technology

D-3263 HCl may stabilize disease in patients with advanced prostate cancer

Experiments illuminate mechanism of action of CXB-909

Convergence Pharma and Selcia collaborate on drug candidates for chronic pain

U.S. DoD recommends funding development of STA-9584 for prostate cancer

CIS Bio withdraws E.U. marketing authorization for NeoSpect

Omthera agrees with FDA on special protocol assessment for Epanova trial

Neurocrine Biosciences completes Daisy Petal trial of elagolix in endometriosis

Mimetogen Pharma's MIM-D3 enters phase II trial in dry eye syndrome

Ono Pharma announces highlights of first half fiscal year 2010

Basilea Pharma begins phase I trial of BAL-30072 for in-hospital infections

Bionor Pharma reverses decision to terminate development of Vacc-4x

Evotec and Merck KGaA join to develop preclinical candidates for neurological disease

FDA places Helix BioPharma's phase II/III IND application for topical interferon alfa-2b on hold

Nerviano Medical Sciences claims new HSP 90 inhibitors

New modulators discovered of metabotropic glutamate mGlu5 receptor

New Juvista formulation for children significantly improves scar appearance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...